Cornell Research Foundation Inc.

Neil R Hackett

Ronald G Crystal

Todd K Rosengart

Yadi Tan

Xiaohuai Zhou

The invention provides a gene transfer vector comprising a humanized nucleic acid sequence encoding an immunogenic portion of one or more exotoxins ofand a heterologous sorting signal. The invention also provides a method of producing an immune response againstin a host comprising administering to the host the gene transfer vector.

Genetic vaccines directed against bacterial exotoxins

The invention provides an isolated or purified nucleic acid molecule comprising SEQ ID NO:1, which contains cDNA comprising exons 1-5 of a vascular endothelial growth factor (VEGF) joined to genomic DNA comprising introns 5, 6, and 7 and exons 6, 7, and 8 of VEGF and a mutation in one or more of the splice donor, branch point, and splice acceptor regions, which promotes the production of a VEGFisoform. Expression constructs, compositions, and cells comprising such a nucleic acid molecule also are provided by the invention.

Alternatively spliced nucleic acid molecules

The present invention provides a method of expressing an exogenous nucleic acid in a mammal. The method comprises non-systemically administering to a non-neuronal tissue of said mammal an exogenous nucleic acid operatively linked to a promoter. The exogenous nucleic acid is proximal to at least one native parvoviral inverted terminal repeat and does not require encapsidation. The expression of the exogenous nucleic acid in the tissue is not substantially diminished at 28 days after administration of the exogenous nucleic acid.

Growing community of inventors

New York, NY, United States of America

Neil R Hackett